IDiyas

For the Inventor, By the Inventor

Downingtown, PA, United States of America

Diane E Gingrich

USPTO Granted Patents = 16


 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 80(Granted Patents)


Location History:

  • Exton, PA (US) (2000 - 2002)
  • Downington, PA (US) (2007 - 2014)
  • Downingtown, PA (US) (2003 - 2016)

Company Filing History:

goldMedal15 out of 247 
 
Cephalon, Inc.
 patents
silverMedal1 out of 730 
 
Kyowa Hakko Kogyo Co., Ltd.
 patents
bronzeMedal1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2000-2016

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 9238656 - Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders (2016-01-19),
2. 8633173 - Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives (2014-01-21),
3. 8552186 - Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors (2013-10-08),
4. 8501936 - Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives (2013-08-06),
5. 8471005 - Pyrrolotriazines as ALK and JAK2 inhibitors (2013-06-25),
6. 8383813 - Fused pyrrolocarbazoles (2013-02-26),
7. 8354414 - Substituted bicyclic pyrimidines (2013-01-15),
8. 8148391 - Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors (2012-04-03),
9. 7851468 - Substituted pyrazolo[3,4-d]pyrimidines (2010-12-14),
10. 7671064 - Fused pyrrolocarbazoles (2010-03-02),
11. 7230026 - Selected fused pyrrolocarbazoles (2007-06-12),
12. 7169802 - Fused pyrrolocarbazoles (2007-01-30),
13. 7115613 - Selected fused pyrrolocarbazoles (2006-10-03),
14. 6630500 - Selected fused pyrrolocarbazoles (2003-10-07),
15. 6451786 - 3′-epimeric k-252a derivatives (2002-09-17),

Title: The Innovative Contributions of Diane E Gingrich

Introduction

Diane E Gingrich is a prominent inventor based in Downingtown, PA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for the treatment of proliferative disorders. With a total of 16 patents to her name, her work has had a substantial impact on medical research and treatment options.

Latest Patents

Among her latest patents is the development of imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders. This application relates to compounds of the Formula I as defined herein, and/or salts thereof. It further discusses compositions and methods of using these compounds and/or salts for therapeutic purposes. Another notable patent involves the preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives. This application pertains to compounds of the general Formula I and/or salts thereof, which are useful in inhibiting JAK2 in subjects needing treatment for related diseases or disorders.

Career Highlights

Diane has worked with notable companies in the pharmaceutical industry, including Cephalon, Inc. Her extensive experience in research and development has allowed her to contribute to innovative solutions in medicine.

Collaborations

Throughout her career, Diane has collaborated with esteemed colleagues such as Robert L Hudkins and James L Diebold. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Diane E Gingrich's contributions to the field of pharmaceuticals through her patents and collaborations highlight her role as a leading inventor. Her work continues to influence the development of treatments for proliferative disorders, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…